According to James Cullem, Cell Signaling Technology, Inc.’s past extension of its patent portfolio covering the unique class of motif-specific, context-independent antibodies was a pivotal step in the company’s leadership in phosphoproteomic discovery. James Cullem served almost 7 years as the company’s Director of Intellectual Property & Licensing, as well as Chief Counsel, and was directly responsible for writing and obtaining those crucial patents worldwide. He highlights that these unique antibodies have been employed to substantially advance the elucidation of cellular signaling pathways and defects in tumor cells, and have aided the identification of novel diagnostic biomarkers and drug targets in cancer.
Given his tremendous expertise in cancer diagnostics and genomics, entrepreneur and business executive James Cullem is well positioned to speak to these research advancements. He formerly served as a co-chair with the Boston Patent Law Association and retains membership rights with a broad range of industry organizations.
James Cullem notes that a broad patent portfolio was secured on this core antibody technology, including the United States, Japan, Canada, and Europe. He noted that these unique antibodies were the basis for the company’s subsequent development of its highly valuable and successful PhosphoScan(R) discovery technology, which allows a simple, 2-step analysis of global cellular phosphorylation activity greatly desired by drug developers. By maintaining a global vision, says James Cullem, Cell Signaling Technology has been able to transform the complex and crucial field of phosphoproteomics and tumor biology.
Established in 1999 as a spin-out from New England Biolabs, Inc., Cell Signaling Technology is a world renowned leader in the phosphoproteomics discovery space, providing top quality reagents and unique discovery technologies to the drug development and academic sectors. The company is headquartered in Danvers, Massachusetts.